Business
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
-- Integrated sperm preparation and intratubal insemination drive earlier intervention and streamlined, in-office care within routine OB/GYN practice -- ATLANTA, May 05, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the first revenue-generating commercial use of its fertility portfolio in the OBGYN setting, led by Fema
About this update from Femasys Inc.
[{"type":"image","alt":"Femasys Inc.","displaySize":"","headline":null,"caption":"Femasys Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":122,"url":"https://media.zenfs.com/en/globenewswire.com/301b83514d43baad2f5211eaa290a825"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2GAPMaOqvqggyHfSDG8ZUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MQ--/https://media.zenfs.com/en/globenewswire.com/301b83514d43baad2f5211eaa290a825","width":300,"height":122}},"lazy":false},{"type":"text","content":"-- Integrated sperm preparation and intratubal insemination drive earlier intervention and streamlined, in-office care within routine OB/GYN practice --","length":152,"tagName":"p"},{"type":"text","content":"ATLANTA, May 05, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the first revenue-generating commercial use of its fertility portfolio in the OBGYN setting, led by FemaSeed as a first-line infertility treatment. The procedure was supported by FemSperm®, enabling in-office sperm preparation and advancing the shift of fertility care to women’s primary physician, where earlier intervention can improve access and outcomes.","length":601,"tagName":"p"},{"type":"text","content":"Infertility impacts an estimated 10 million women in the United States, yet fewer than 1% receive care at specialized fertility centers, highlighting a significant gap in treatment access. This disparity is further underscored by recent CDC data showing U.S. fertility rates declined to record lows in 2025, continuing a long-term downward trend. By enabling fertility care within the OBGYN setting, where most women already receive care, Femasys is addressing this unmet need with earlier access to intervention at a meaningfully lower cost and reduced procedural complexity than IVF. This approach enables OBGYNs to offer a new in-office fertility treatment option, supporting practice growth while shifting the care pathway toward more timely, cost-efficient, and patient-centered treatment.","length":794,"tagName":"p"},{"type":"text","content":"“Femasys is leading a fundamental shift in fertility care by moving treatment earlier and closer to the patient,” said Kathy Lee-Sepsick, Founder a...